{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:57:14Z","timestamp":1775285834260,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s13365-018-0688-3","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T14:17:02Z","timestamp":1543241822000},"page":"85-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-7242","authenticated-orcid":false,"given":"Michael R.","family":"Keegan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Boasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"688_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(88)90813-0","volume":"90","author":"P Andine","year":"1988","unstructured":"Andine P, Lehmann A, Ellren K et al (1988) The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci Lett 90:208\u2013212","journal-title":"Neurosci Lett"},{"key":"688_CR2","first-page":"31","volume":"9","author":"AAB Badawy","year":"2016","unstructured":"Badawy AAB, Dougherty DM (2016) Assessment of the human kynurenine pathway: comparisons and clinical implications of ethnic and gender differences in plasma tryptophan, kynurenine metabolites, and enzyme expressions at baseline and after acute tryptophan loading and depletion. Int J Tryptophan Res 9:31\u201349","journal-title":"Int J Tryptophan Res"},{"issue":"10","key":"688_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s007020070026","volume":"107","author":"H Baran","year":"2000","unstructured":"Baran H, Hainfellner JA, Kepplinger B, Mazal PR, Schmid H, Budka H (2000) Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm 107(10):1127\u20131138","journal-title":"J Neural Transm"},{"key":"688_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/138920007780362527","volume":"8","author":"A Boasso","year":"2007","unstructured":"Boasso A, Shearer GM (2007) How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr Drug Metab 8:217\u2013223","journal-title":"Curr Drug Metab"},{"key":"688_CR5","unstructured":"Bracchi M, Pagani N, Clarke A, Adams T, Waters L, Bolton M, et al (n.d.) Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system toxicity. International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK, p 209"},{"key":"688_CR6","doi-asserted-by":"crossref","unstructured":"British HIV Association (BHIVA) (n.d.) Guidelines for the treatment of hiv-1-positive adults with antiretroviral therapy 2015 (2016 Interim Update). http:\/\/www.bhiva.org\/HIV-1-treatment-guidelines.aspx","DOI":"10.21864\/jbgtha.2016.13"},{"issue":"3","key":"688_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/infdis\/jiu115","volume":"10","author":"H Byakwaga","year":"2014","unstructured":"Byakwaga H, Boum Y, Huang Y, Muzoora C, Kembabazi A, Weiser SD et al (2014) The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis 10(3):383\u2013391","journal-title":"J Infect Dis"},{"issue":"12","key":"688_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3109\/00207454.2010.520541","volume":"120","author":"GIT Cavalcante","year":"2010","unstructured":"Cavalcante GIT, Capistrano VLM Jr, Cavalcante FSD, Vasconcelos DS, Macedo DS, Sousa FCF et al (2010) Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci 120(12):739\u2013745","journal-title":"Int J Neurosci"},{"issue":"7","key":"688_CR9","doi-asserted-by":"publisher","first-page":"e100446","DOI":"10.1371\/journal.pone.0100446","volume":"9","author":"J Chen","year":"2014","unstructured":"Chen J, Shao J, Cai R, Shen Y, Zhang R, Liu L, Qi T, Lu H (2014) Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients. PLoS One 9(7):e100446","journal-title":"PLoS One"},{"key":"688_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4137\/IJTR.S4321","volume":"3","author":"NWS Davies","year":"2010","unstructured":"Davies NWS, Guillemin G, Brew BJ (2010) Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder. Int J Tryptophan Res 3:121\u2013140","journal-title":"Int J Tryptophan Res"},{"key":"688_CR11","unstructured":"European AIDS Clinical Society (EACS) (n.d.) Guidelines Version 8.1, October 2016. http:\/\/www.eacsociety.org\/files\/guidelines_8.1-english.pdf"},{"issue":"4","key":"688_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/QAI.0000000000001269","volume":"74","author":"A Fettiplace","year":"2016","unstructured":"Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V et al (2016) Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr 74(4):423\u2013431","journal-title":"J Acquir Immune Defic Syndr"},{"key":"688_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0304-3940(84)90050-8","volume":"48","author":"AC Foster","year":"1984","unstructured":"Foster AC, Vezzani A, Frencg ED, Schwarz R (1984) Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 48:273\u2013278","journal-title":"Neurosci Lett"},{"key":"688_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/jir.1990.10.599","volume":"10","author":"D Fuchs","year":"1990","unstructured":"Fuchs D, Forsman A, Hagberg L, Larsson G, Norkrans G, Reignegger G et al (1990) Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interf Res 10:599\u2013603","journal-title":"J Interf Res"},{"key":"688_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0165-2478(91)90005-U","volume":"28","author":"D Fuchs","year":"1991","unstructured":"Fuchs D, Moller AA, Reibnegger G, Werner ER, Werner-Felmayer G, Dierich MP et al (1991) Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 28:207\u2013212","journal-title":"Immunol Lett"},{"key":"688_CR16","unstructured":"Grill M, Gisslen M, Cinque P, Peterson J, Lee E, Spudich S, et al (n.d.) Kynurenine-tryptophan and phenylalanine-tyrosine levels in cerebrospinal fluid in HIV infection. 19th Conference on Retroviruses and Opportunistic Infections, 5\u20138 March 2012, Seattle, WA, p 463"},{"key":"688_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4615-0135-0_12","volume":"527","author":"GJ Guillemin","year":"2003","unstructured":"Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ (2003) Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 527:105\u2013112","journal-title":"Adv Exp Med Biol"},{"key":"688_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/glia.20090","volume":"49","author":"GJ Guillemin","year":"2004","unstructured":"Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2004) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49:15\u201323","journal-title":"Glia"},{"issue":"2","key":"688_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2016.8900","volume":"316","author":"HF Gunthard","year":"2016","unstructured":"Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE et al (2016) Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 316(2):191\u2013210","journal-title":"JAMA"},{"key":"688_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0165-5728(92)90214-6","volume":"40","author":"MP Heyes","year":"1992","unstructured":"Heyes MP, Brew BJ, Saito K, Quearry BJ, Price RW, Lee K, Bhalla RB, der M, Markey SP (1992) Inter-relationships between quinolinic acid, neuroactivity, kynurenines, neopterin and \u03b2 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol 40:71\u201380","journal-title":"J Neuroimmunol"},{"key":"688_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4137\/IJTR.S36464","volume":"9","author":"MR Keegan","year":"2016","unstructured":"Keegan MR, Chittiprol S, Letendre SL, Winston A, Fuchs D, Boasso A, Iudicello J, Ellis RJ (2016) Tryptophan metabolism and its relationship with depression and cognitive impairment among HIV-infected individuals. Int J Tryptophan Res 9:79\u201388","journal-title":"Int J Tryptophan Res"},{"key":"688_CR22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/clinchem\/48.3.579","volume":"48","author":"A Laich","year":"2002","unstructured":"Laich A, Neurauter G, Widner B, Fuchs D (2002) More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 48:579\u2013581","journal-title":"Clin Chem"},{"issue":"4","key":"688_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jnr.490230410","volume":"23","author":"M Larsson","year":"1989","unstructured":"Larsson M, Hagberg L, Norkrans G, Forsman A (1989) Indoleamine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection. J Neurosci Res 23(4):441\u2013446","journal-title":"J Neurosci Res"},{"issue":"4","key":"688_CR24","first-page":"324","volume":"1","author":"JM Launay","year":"1988","unstructured":"Launay JM, Copel L, Callebert J, Corva\u00efa N, Lepage E, Bricaire F, Saal F, Peries J (1988) Decreased whole blood 5-hydroxytryptamine (serotonin) in AIDS patients. J Acquir Immune Defic Syndr 1(4):324\u2013325","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"688_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/FPC.0000000000000145","volume":"25","author":"EM McDonagh","year":"2015","unstructured":"McDonagh EM, Lau JL, Alvarellos M, Altman RB, Klein TE (2015) PharmGKB summary: efavirenz pathway, phamacokinetcs (PK). Pharmacogenet Genomics 25(7):363\u2013376","journal-title":"Pharmacogenet Genomics"},{"key":"688_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/138920007780362509","volume":"8","author":"MF Murray","year":"2007","unstructured":"Murray MF (2007) The human indoleamine 2,3-dioxygenase gene and related human genes. Curr Drug Metab 8:197\u2013200","journal-title":"Curr Drug Metab"},{"issue":"5","key":"688_CR27","first-page":"388","volume":"18","author":"K Robertson","year":"2012","unstructured":"Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neuro-Oncol 18(5):388\u2013399","journal-title":"J Neuro-Oncol"},{"key":"688_CR28","unstructured":"Rowlands J, Higgs C, De Esteban N, McKenna S, Perry N, Winston A, et al (n.d.) Multicenter open-label study of switching from atripla to eviplera for CNS toxicity. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5\u20139, 2014. Washington, DC. Abstract H-1005"},{"issue":"3","key":"688_CR29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0031-6997(25)00441-7","volume":"45","author":"TW Stone","year":"1993","unstructured":"Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45(3):309\u2013379","journal-title":"Pharmacol Rev"},{"key":"688_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MCO.0000000000000237","volume":"19","author":"B Strasser","year":"2016","unstructured":"Strasser B, Gostner JM, Fuchs D (2016) Mood, food and cognition: role of tryptophan and serotonin. Curr Opin Clin Nutr Metab Care 19:55\u201361","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"688_CR31","unstructured":"Summary of product characteristics, Sustiva\u00ae. Last updated on eMC 01-Nov-2016"},{"issue":"3","key":"688_CR32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1124\/jpet.112.195701","volume":"343","author":"LB Tovar-y-Romo","year":"2012","unstructured":"Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ (2012) Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 343(3):696\u2013703","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"688_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/QAD.0000000000000538","volume":"29","author":"J Underwood","year":"2015","unstructured":"Underwood J, Robertson KR, Winston A (2015) Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS 29(3):253\u2013261","journal-title":"AIDS"},{"key":"688_CR34","unstructured":"United States Department of Health & Human Services (DHHS) (n.d.) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 14th July 2016. http:\/\/aidsinfo.nih.gov\/guidelines"},{"key":"688_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/QAD.0b013e328341685b","volume":"25","author":"L Waters","year":"2011","unstructured":"Waters L, Fisher M, Winston A, Higgs C, Hadley W, Garvey L, Mandalia S, Perry N, Nicola M, Nelson M (2011) A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 25:65\u201371","journal-title":"AIDS"},{"key":"688_CR36","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1093\/clinchem\/43.12.2424","volume":"43","author":"B Widner","year":"1997","unstructured":"Widner B, Werner ER, Schennach H, Wachter H, Fuchs D (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43:2424\u20132426","journal-title":"Clin Chem"},{"key":"688_CR37","unstructured":"Yapa HM, Waters L, Rowlands J, Jackson A, Madndalia S, Higgs C, et al (n.d.) The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a phase IV open label pilot study. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, June 30\u2013July 3, 2013, Kuala Lumpur. Abstract MOPE090"},{"key":"688_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1006\/clim.2002.5231","volume":"104","author":"R Zangerle","year":"2002","unstructured":"Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D (2002) Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol 104:242\u2013247","journal-title":"Clin Immunol"},{"key":"688_CR39","volume-title":"Neuroprotective mechanisms of nevirapine and efavirenz in a model of neurodegeneration","author":"GT Zheve","year":"2007","unstructured":"Zheve GT (2007) Neuroprotective mechanisms of nevirapine and efavirenz in a model of neurodegeneration. Rhodes University, Rhodes"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-018-0688-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:02:11Z","timestamp":1775282531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-018-0688-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s13365-018-0688-3","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"15 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study team complied with the ethical principles for medical research involving human subjects as defined by the World Medical Associations\u2019 Declaration of Helsinki. This study was reviewed and approved by the London Research Ethics Committee (REC reference 14\/LO\/1493, Date 31\/10\/2014; EudraCT number 2013-004729-94).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ViiV Healthcare Ltd. provided full financial support and supply of dolutegravir for the study. The authors confirm that the funders had no influence over the study design, content of the article, or selection of this journal.Michael Keegan participated in this work as part of a PhD, which is being conducted at Imperial College London and is sponsored with an unrestricted grant by ViiV Healthcare Ltd. He is an employee and shareholder in ViiV Healthcare Ltd.Mark Nelson has received payments from ViiV Healthcare Ltd. for advisory board participation and travel.Alan Winston has received speaker fees and investigator-initiated grants from ViiV Healthcare Ltd.Dietmar Fuchs, Chris Higgs and Adriano Boasso declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}